• 1
    Boring CC, Squire TS, Tong T. Cancer statistics. CA Cancer J Clin 1992; 42: 1838.
  • 2
    Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancer. Science 1991; 253: 4953.
  • 3
    Raybaud-Diogene H, Tetu B, Morecy R, Fortin A, Monteil RA. p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Oral Oncol, Eur J Cancer 1996; 32B: 1439.
  • 4
    Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 485578.
  • 5
    Boyle JO, Hakim J, Koch W. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 447780.
  • 6
    Shahnavaz SA, Regezi JA, Bradley G, Dube ID, Jordan RCK. p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas. J Pathol 2000; 190: 41722.
  • 7
    Nees M, Homann N, Discher H, Andl T, Enders C, Herold-Mende C, Schuhmann A, Bosch FX. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 1993; 53: 418996.
  • 8
    Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P, Frebourg T, Iggo R. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997; 14: 1639.
  • 9
    Van Houten VM, Tabor MP, van den Brekel WM, Denkers F, Wishaupt RGA, Kummer JA, Snow GB, Brakenhoff RH. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin Cancer Res 2000; 6: 380316.
  • 10
    Ahomadegbe JC, Barrois M, Fogel S, LeBihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases: absence of correlation with clinical outcome—frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10: 121727.
  • 11
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 70920.
  • 12
    Saunders ME, Mackenzie R, Shipman R, Fransen E, Gilbert R, Jordan RC. Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy. Clin Cancer Res 1999; 5: 245563.
  • 13
    Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage S, Jen J, Sidransky D. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci USA 1999; 96: 73829.
  • 14
    Wikman FP, Lu M-L, Thykjaer T, Olesen SH, Andersen LD, Cordon-Cardo C, Orntoft TF. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem 2000; 46: 155561.
  • 15
    Wen W-H, Bernstein L, Lescallett J, Beazer-Barclay Y, Sullivan-Halley J, White M, Press MF. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 2000; 60: 271622.
  • 16
    Kropveld A, Rozemuller EH, Leppers FGJ, Scheidel KC, de Weger RA, Koole R, Hordijk GJ, Slootweg PJ, Tilanus MG. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 1999; 79: 34753.
  • 17
    Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003; 63: 118891.
  • 18
    Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993; 68: 5408.
  • 19
    Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsuhsita K, Saito H, Hotta T. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337: 52934.
  • 20
    Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, Moriya Y, van de Velde CJ, van Krieken JH. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001; 195: 1718.
  • 21
    Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002; 99: 597602.
  • 22
    Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003; 21: 2716.
  • 23
    Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 34655.
  • 24
    Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 102934.
  • 25
    Berns EMJJ, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WLJ, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJC, Portengen H, Bakker B, Klijn JGM. Complete sequencing of p53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000; 60: 215562.
  • 26
    Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 2000; 6: 44351.
  • 27
    Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen–Dale AL. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 250512.
  • 28
    Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 678893.
  • 29
    van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000; 6: 213845.
  • 30
    Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, Yoo GH, Lee DJ, Forastiere AA, Sidransky D. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 15806.
  • 31
    Mineta H, Borg A, Dictor M, Akervall J, Wennerberg J. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998; 78: 108490.
  • 32
    Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, Weidauer H, Bosch FX. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998; 16: 16719.
  • 33
    Bradford CR, Zhu S, Poore J, Fisher SG, Beals TF, Thoraval D, Hanash SM, Carey TE, Wolf GT. p53 mutation as a prognostic marker in advanced laryngeal carcinoma: Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg 1997; 123: 6059.
  • 34
    Bradford CR, Wolf GT, Carey TE, Zhu S, Poore J, Beals TF, Truelson JM, McClatchey KD, Fisher SG. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg 1999; 121: 5348.
  • 35
    Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, Heyne K, Shin HJ, Ro JY, Goepfert H, Hong WK, Hittelman WN. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 51929.
  • 36
    Maestro R, Dolcetti R, Gasparotto D, Dolglioni C, Pelucchi S, Barzan L, Grandi E, Boiocchi M. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992; 7: 115966.
  • 37
    Sauter ER, Ridge JA, Gordon J, Eisenberg BL. p53 overexpression correlates with increased survival in patients with squamous carcinoma of the tongue base. Am J Surg 1992; 164: 6513.
  • 38
    Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolin A, Bevilacqua P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous carcinoma. Int J Cancer 1993; 55; 73944.
  • 39
    Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1: 23340.
  • 40
    Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998; 58: 513.
  • 41
    Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000; 89: 3004.
  • 42
    van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B, Denkers F, Smeele LE, Snow GB, Brakenhoff RH. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001; 93: 2325.
  • 43
    Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21: 15107.
  • 44
    Vaziri H, Dessain SK, Eaton EN, Imai S-I, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 14959.
  • 45
    Luo J, Nikolaev AY, Imai S-I, Chen D, Su F, Shiloh A, Guarente L, Gu W. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 2001; 107: 13748.
  • 46
    Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh J-K, Zhong S, Campargue I, Naumovski L, Crook T, Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 78194.
  • 47
    Gottifredi V, Prives C. p53 and PML: new partners in tumor suppression. Trends Cell Biol 2001; 11: 1847.
  • 48
    Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh J-K, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, Lu X. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33: 1627.
  • 49
    Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, Chou TC, Ocharoenrat P, Levine AJ, Rao PH, Stoffel A. p53 regulates cell survivalby inhibiting PIK3CA in squamous cell carcinomas. Genes Develop 2002; 16: 98493.
  • 50
    Brennan JA, Mao LM, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D. Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med 1995; 332: 42935.
  • 51
    Partridge M, Li SR, Pateromichelakis S, Francis R, Philipps E, Huang XH, Tesfa-Selase F, Langdon JD. Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clin Cancer Res 2000; 6: 271825.
  • 52
    Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittelman W, Hong WK. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2: 6825.
  • 53
    Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu X-C, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: ten years of translation research. Clin Cancer Res 2000; 6: 170210.